However, the efficacy of first-generation EGFR-TKIs for treating NSCLC-BM is limited by blood-brain barrier (BBB) penetration and exon 20 (T790M) tumor mutations [14,15]. Here, EGFR is linked to non-small cell lung carcinoma.